Abstract 2512
Background
Activation of AXL receptor tyrosine kinase is a key mediator of epithelial to mesenchymal transition (EMT). AXL is overexpressed in several human cancers, including CRC.
Methods
AXL expression was assessed by immunohistochemistry in tumor samples from 346 mCRC pts treated at three Institutions and enrolled in different clinical trials (CAPRI, MACBETH, MOMA, TRIBE2). In silico data of AXL RNA levels were obtained from GSE5851 dataset, including 80 pts with advanced mCRC treated with cetuximab in a later line.
Results
AXL expression was found in 18% of cases within tumor cells, with no difference among RAS cohorts. In the RAS WT group, AXL positive pts had a worse mPFS whether treated with chemotherapy (CT) + anti-EGFR [6.2 m (CI95% 4.2- 8.2) vs 12.1 m (CI95% 10.6 – 13.6) p 0.012] or CT+anti-angiogenic agent [6.7 m (CI95% 8.9- 19.3) vs 14.1 m (CI95% 9.4– 13.0) p 0.007], whereas in RAS mutant pts no impact on PFS was observed. AXL expression correlated with worse mOS in both cohorts; notably, in RAS WT pts mOS was 19.9 m (CI95% 10.5- 29.2) vs 37.6 m (CI95% 31.1– 44.1) p 0.006]. In tumor stroma, assessable in 334 samples, AXL was expressed in 80% of cases, with no difference among RAS groups. AXL expression correlated with lower mOS in both cohorts. (Table) Intriguingly, AXL expression in tumor and stroma (+/+) correlated with shorter mOS; in particular, RAS WT pts (+/+) had a mOS of 19.9 m (CI95% 8.0- 31.7) vs (-/-) 50.1 m (CI95% 43.9- 56.2) p 0.004]. In silico analyses showed high AXL RNA levels in 50% of pts. Moreover, in this population treated with cetuximab, in the KRAS exon2 WT cohort (N = 43) AXL high pts had worse mPFS [1.9 m (CI95% 1.7 -2.0) vs 3.8 m (CI95% 0.7-6.7) p 0.59].Table: 121P
Cohort | AXL expression in tumor cells | AXL expression in stroma | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
N | Negative <1% (%) | Positive ≥1% (%) | PFS months p value | OS months p value | N | Negative <1% (%) | Positive ≥1% (%) | PFS months p value | OS months p value | |
Overall population | 346 | 285 (82) | 61 (18) | 10.7 vs 8.0 0.008 | 32.4 vs 23.0 0.007 | 334 | 66 (20) | 268 (80) | 10.7 vs 8.0 0.11 | 41.1 vs 28.5 0.004 |
RAS WT (overall) | 175 | 147 (84) | 28 (16) | 12.3 vs 6.6 <0.000 | 37.6 vs 19.9 0.006 | 167 | 33 (20) | 134 (80) | 15.0 vs 10.7 0.034 | 49.8 vs 33.5 0.031 |
RAS WT CT + anti-EGFR | 136 | 114 (84) | 22 (16) | 12.1 vs 6.2 0.012 | 35.8 vs 23.0 0.087 | 129 | 18 (14) | 111 (86) | 14.3 vs 10.4 0.37 | 44.4 vs 33.5 0.11 |
RAS WT CT + anti-angiogenic | 39 | 33 (85) | 6 (15) | 14.1 vs 6.7 0.007 | 44.8 vs 13.2 0.004 | 38 | 15 (39) | 23 (61) | 15.0 vs 11.0 0.12 | 50.1 vs 40.6 0.17 |
RAS mut (overall) CT + anti-angiogenic | 171 | 138 (81) | 33 (19) | 9.6 vs 8.9 0.78 | 27.6 vs 23.7 0.33 | 167 | 33 (20) | 134 (80) | 9.7 vs 9.2 0.98 | 35.5 vs 24.7 0.056 |
Conclusions
AXL expression in tumor and stroma might have a negative prognostic relevance in mCRC. In RAS WT pts, AXL expression might represent a predictive biomarker of lack of efficacy for both anti-EGFR and anti-angiogenic agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli".
Funding
AIRC MFAG-2015-ID: 7778.
Disclosure
F. Ciardiello: Advisory / Consultancy, Advisory Board: Merck KgA, Bayer, Amgen, Roche, Servier, Pfizer. E. Martinelli: Advisory / Consultancy: Merck KgA, Amgen, Bayer, Roche, Sanofi, Servier. All other authors have declared no conflicts of interest.
Resources from the same session
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract